In addition, an anti-diabetes drug, empagliflozin, has been reported to promote AMPK1/ULK1/FUNDC1-dependent mitophagy and attenuated mitochondrial dysfunction in both in vitro and in vivo I/R injury models (Cai et al., 2022). The gene discussed is PRKAA1; the disease is diabetes mellitus.